Page last updated: 2024-12-08

nk3201

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NK3201: inhibits vascular proliferation in grafted vein [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	213050
SCHEMBL ID	4350497
MeSH ID	M0403206

Synonyms (15)

Synonym
nk-3201
nk3201
nk 3201
204460-24-2
SCHEMBL4350497
n-(3,4-dioxo-1-phenyl-7-pyridin-2-yloxyheptan-2-yl)-2-(5-formamido-6-oxo-2-phenylpyrimidin-1-yl)acetamide
(2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-n-(3,4-dioxo-1-phenyl-7-(2-pyridyloxy)-2-heptyl)acetamide)
n-(1-benzyl-2,3-dioxo-6-(2-pyridyloxy)hexyl)-2-(5-(formylamino)-6-oxo-2-phenyl-1,6-dihydropyrimidin-1-yl)acetamide
gtpl6503
AKOS030531107
n-{3,4-dioxo-1-phenyl-7-[(pyridin-2-yl)oxy]heptan-2-yl}-2-{5-[(hydroxymethylidene)amino]-6-oxo-2-phenylpyrimidin-1(6h)-yl}ethanimidic acid
DTXSID90942622
Q27087942
1(6h)-pyrimidineacetamide, n-[2,3-dioxo-1-(phenylmethyl)-6-(2-pyridinyloxy)hexyl]-5-(formylamino)-6-oxo-2-phenyl-
cid 213050

Research Excerpts

Overview

NK3201 is an orally active chymase inhibitor.

Excerpt	Reference	Relevance
"NK3201 is an orally active chymase inhibitor. "	( Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation. Miyazaki, M; Takai, S, 2003)	2.04

Treatment

Excerpt	Reference	Relevance
"NK3201 treatment starting 3 days before MI significantly inhibited the increase in cardiac chymase activity, while it did not affect ACE activity either in plasma or in heart 3 days after MI."	( Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Ishida, K; Jin, D; Kamoshita, K; Miyazaki, M; Sakaguchi, M; Sukenaga, Y; Takai, S; Yamada, M, 2003)	1.04

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID1345820	Human chymase 1 (S1: Chymotrypsin)	2004	The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3	A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (94.44)	29.6817
2010's	1 (5.56)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	16.47 (24.57)
Research Supply Index	2.94 (2.92)
Research Growth Index	4.23 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (16.47)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	4 (22.22%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (77.78%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	3.18	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	3.18	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	4.23	5	amino acid zwitterion; angiotensin II	human metabolite
nadp [no description available]	2.05	1
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.05	1	4-hydroxynon-2-enal; 4-hydroxynonenal
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.72	3
angiotensin i Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.. angiotensin I : A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.. angiotensin I dizwitterion : A peptide zwitterion that is the dizwitterionic form of angiotensin I having both carboxy groups deprotonated and the aspartyl amino group and arginine side-chain protonated. It is the major species at pH 7.3.	2	1	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent

Condition	Relationship Strength	Studies
Abdominal Aortic Aneurysm [description not available]	7.72	3
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.86	4
Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.	2.72	3
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.44	2
Cardiac Remodeling, Ventricular [description not available]	3.35	2
Anoxemia [description not available]	2.05	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.05	1
Auricular Fibrillation [description not available]	3	1
Cardiac Failure [description not available]	3	1
Blood Pressure, High [description not available]	3.83	2
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	3	1
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	3.83	2
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	3	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	3.83	2
Cardiovascular Stroke [description not available]	3.62	3
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	3.62	3
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	7.71	3
Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts.	3.33	2
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	2.93	1
Alveolitis, Fibrosing [description not available]	2.02	1
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	7.02	1
Constriction, Pathological [description not available]	2.43	2
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	2.43	2
Cirrhosis [description not available]	2.03	1
Cardiac Diseases [description not available]	2.03	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.03	1
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.03	1
Disease Exacerbation [description not available]	2.03	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.04	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2	1

chemdatabank.com